nach oben

Erschienen in:

01.12.2009

A study on MSH2 and MLH1 mutations in hereditary nonpolyposis colorectal cancer families from the Basque Country, describing four new germline mutations

verfasst von: Cristina Martínez-Bouzas, Elena Beristain, Enrique Ojembarrena, Jose Errasti, Karmele Mujika, Noelia Viguera, Maria Isabel Tejada

Erschienen in: Familial Cancer | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Hereditary non-polyposis colorectal cancer (HNPCC) or Lynch syndrome underlies between 2 and 5% of all colorectal cancer. It is inherited as an autosomal dominant condition due to mutations in the mismatch repair genes. Fifty-four non-related index cases, 21 of them fulfilling Amsterdam criteria I or II, were studied. Ten (10/21 = 47.6%) different pathological mutations were found in this group, two of which had not previously been reported—one in MLH1 and the other in MSH2-. In the remaining patients, we also found another family with one of these new mutations, and four additional changes, two of which were also new—a pathological change in MSH2 and a second change of uncertain significance in MLH1-, while the other two changes had already been reported. Of all mutations, eight were found in MSH2 (8/15 = 53.3%) and seven in MLH1 (7/15 = 46.6%), suggesting a slightly greater involvement of MSH2 in HNPCC than MLH1 in our population, in contrast to the results reported by other authors.

Piñol V, Andreu M, Castells A et al (2004) Frequency of hereditary nonpolyposis colorectal cancer and other colorectal cancer familial forms in Spain: a multicentre, prospective, nationwide study. Eur J Gastroenterol Hepatol 16(1):39–45CrossRefPubMed

Toribara NW, Sleisenger MH (1995) Screening for colorectal cancer. N Engl J Med 332:861–867CrossRefPubMed

Pistorius S, Gorgens H, Plaschke J et al (2007) Genomic rerrangements in MSH2, MLH1 or MSH6 are rare in HNPCC patients carrying point mutations. Cancer Lett 248(1):89–95CrossRefPubMed

Peltomäki P (2001) Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet 10:735–740CrossRefPubMed

Eng C, Brody LC, Wagner TM et al (2001) Steering committee of the breast cancer information core (BIC) consortium. Interpretation of molecular epidemiologic research: blinded comparison of methods for detecting germline BRCA1 mutation. J Med Genet 38:824–833CrossRefPubMed

International Society for Gastrointestinal Hereditary Tumours (InSight), www.insight-group.org

Lastella P, Surdo NC, Resta N, et al. (2006) In silico and in vivo splicing analysis of MLH1 and MSH2 missense mutations shows exon- and tissue-specific effects. BMC Genomics 7:243

Goecke T, Schulmann K, Engel C et al (2008) Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with lynch syndrome: a report by the German HNPCC consortium. J Clin Oncol 24(26):4285–4292CrossRef

Goldberg Y, Porat RM, Kedar I et al (2008) Mutation spectrum in HNPCC in the Israeli population. Fam Cancer 7(4):309–317CrossRefPubMed

10.

Nytröm-Lahti N, Wu Y, Hoisio AL et al (1996) DNA mismatch repair gene mutations in 55 kindreds with verified or putative hereditary non-polyposis colorectal cancer. Hum Mol Genet 5(6):763–769CrossRef

11.

Wu Y, Nytröm-Lahti N, Osinga J et al (1997) MSH2 and MLH1 mutations in sporadic replication error-positive colorectal carcinoma as assessed by two-dimensional DNA electrophoresis. Genes Chromosom Cancer 18:269–278CrossRefPubMed

12.

Barnetson RA, Cartwright N, van Vliet A et al (2008) Classification of ambiguous mutations in DNA mismatch repair genes identifies in a population-based study of colorectal cancer. Hum Mutat 29(3):367–374CrossRefPubMed

13.

Martinez-Bouzas C, Ojembarrena E, Beristain E et al (2007) High proportion of large genomic rearrangements in hMSH2 in hereditary nonpolyposis colorectal cancer (HNPCC) families of the Basque Country. Cancer Lett 255:295–299CrossRefPubMed

14.

Mangold E, Pagenstecher C, Friedl W et al (2005) Propping and the German HNPCC consortium, spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1721 German families suspected of hereditary nonpolyposis colorectal cancer. Int J Cancer 116:692–702CrossRefPubMed

15.

Perera S, Bapat B (2008) The MLH1 variants p.Arg265Cys and p.Lys618Ala affect protein stability while p.Leu749Gln affects heterodimer formation. Hum Mutat 29(2):332CrossRefPubMed

16.

Ollila S, Sarantaus L, Kariola R et al (2006) Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein. Gastroenterology 131:1408–1417CrossRefPubMed

17.

Devlin LA, Graham CA, Price JH, Morrison PJ (2008) Germline MSH6 mutations are more prevalent in endometrial cancer patient cohorts than hereditary non polyposis colorectal cancer cohorts. Ulst Med J 77(1):25–30

18.

Martinez-Bouzas C, Beristain E, Errasti J et al (2007) Nueva mutación en MLH1: c.306+5G>A produce un nuevo sitio de splice en una familia con cáncer de colon no poliposico. Paper presented at the XXIV Congreso Nacional de Genética Humana. Alicante 19–21 Septiembre 2007

19.

Pineda M, Blanco I, Llort G et al (2007) Identificación de dos mutaciones recurrentes en MLH1 en nuestra población. Paper presented at the XXIV Congreso Nacional de Genética Humana. Alicante 19–21 Septiembre 2007

20.

Ewald J, Rodrigue CM, Mourra N et al (2007) Immunohistochemical staining for mismatch repair proteins, and its relevance in the diagnosis of hereditary non-polyposis colorectal cancer. Br J Surg 94(8):1020–1027CrossRefPubMed

21.

Belvederesi L, Bianchi F, Loretelli C et al (2006) Assessing the pathogenicity of MLH1 missense mutations in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic and functional features. Eur J Hum Genet 14:853–859CrossRefPubMed

22.

Blasi MF, Ventura I, Aquilina G et al (2006) A human cell-based assay to evaluate the effects of alterations in the MLH1 mismatch repair gene. Cancer Res 66(18):9036–9044

23.

Wagner A, Barrows A, Wijnen JT et al (2003) Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet 72:1088–1100CrossRefPubMed

24.

Taylor CF, Charton RS, Burn J, Sheridan E, Taylor GR (2003) Genomic delections in MSH2 or MLH1 are a frequent cause of hereditary nonpolyposis colorectal cancer: identification of novel and recurrent deletions by MLPA. Hum Mutat 22:428–433CrossRefPubMed

25.

Gile JJ, Hogervost FB, Pals G et al (2002) Genomic delections of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach. Br J Cancer 87:892–897CrossRef

26.

Picelli S, Vandrovcova J, Jones S et al (2008) Genome-wide linkage scan for colorectal cancer susceptibility genes supports linkage to chromosome 3q. BMC Cancer 8:87CrossRefPubMed

27.

Bläker H, Mechtersheimer G, Sutter C et al (2008) Recurrent deletions at 6q in early age of onset non-HNPCC and non-FAD associated intestinal carcinomas. Evidence for novel cancer susceptibility locus at 6q14–q22. Genes Chromosom Cancer 47:159–164CrossRefPubMed

Titel: A study on MSH2 and MLH1 mutations in hereditary nonpolyposis colorectal cancer families from the Basque Country, describing four new germline mutations
verfasst von: Cristina Martínez-Bouzas
Elena Beristain
Enrique Ojembarrena
Jose Errasti
Karmele Mujika
Noelia Viguera
Maria Isabel Tejada
Publikationsdatum: 01.12.2009
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 4/2009
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-009-9283-3

Springer Medizin

A study on MSH2 and MLH1 mutations in hereditary nonpolyposis colorectal cancer families from the Basque Country, describing four new germline mutations

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Methylation not a frequent “second hit” in tumors with germline BRCA mutations

CHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia

Association of MUTYH and MSH6 germline mutations in colorectal cancer patients

Low contribution of BRCA1/2 genomic rearrangement to high-risk breast cancer in the Korean population

Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation

Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie